A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.
Microgravity drug research is expanding from ISS crystal studies to commercial manufacturing efforts. New experiments and a Varda-United Therapeutics collaboration target improved drug stability, delivery and production.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
New research reveals metformin regulates blood sugar through brain pathways involving the Rap1 protein in the hypothalamus. The study shows suppressing Rap1 in the brain prevents metformin from lowering blood sugar in diabetic mice. These findings could lead to new diabetes treatments targeting this brain pathway.
